DK3113795T3 - Rekombinante virale isfahan-vektorer - Google Patents

Rekombinante virale isfahan-vektorer

Info

Publication number: DK3113795T3
Authority: DK; Denmark
Prior art keywords: isfahan; vectors; recombinant viral; viral; recombinant
Prior art date: 2014-03-01

Application number

DK15758863.3T

Other languages

English (en)

Inventor

Demetrius Matassov

Rodion V Gorchakov

Stefan Hamm

Rebecca Nowak

Robert L Seymour

John H Eldridge

Robert B Tesh

David K Clarke

Theresa E Latham

Scott Weaver

Farooq Nasar

Original Assignee

Univ Texas

Profectus Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-01

Filing date

2015-02-27

Publication date

2019-10-21

2015-02-27 Application filed by Univ Texas, Profectus Biosciences Inc filed Critical Univ Texas

2019-10-21 Application granted granted Critical

2019-10-21 Publication of DK3113795T3 publication Critical patent/DK3113795T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16071—Demonstrated in vivo effect
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20241—Use of virus, viral particle or viral elements as a vector
- C12N2760/20243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20261—Methods of inactivation or attenuation
- C12N2760/20262—Methods of inactivation or attenuation by genetic engineering
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20271—Demonstrated in vivo effect
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36171—Demonstrated in vivo effect
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Mycology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Hematology (AREA)
Communicable Diseases (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

DK15758863.3T 2014-03-01 2015-02-27 Rekombinante virale isfahan-vektorer DK3113795T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201461946734P	2014-03-01	2014-03-01
PCT/US2015/018156 WO2015134332A2 (en)	2014-03-01	2015-02-27	Recombinant isfahan viral vectors

Publications (1)

Publication Number	Publication Date
DK3113795T3 true DK3113795T3 (da)	2019-10-21

Family

ID=54055975

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK15758863.3T DK3113795T3 (da)	2014-03-01	2015-02-27	Rekombinante virale isfahan-vektorer

Country Status (14)

Country	Link
US (1)	US9932564B2 (da)
EP (1)	EP3113795B1 (da)
JP (3)	JP2017508465A (da)
KR (1)	KR102416194B1 (da)
CN (1)	CN106794240A (da)
AU (1)	AU2015225553B2 (da)
CA (1)	CA2941261A1 (da)
DK (1)	DK3113795T3 (da)
ES (1)	ES2749381T3 (da)
IL (2)	IL247545B (da)
MX (1)	MX369776B (da)
SG (1)	SG11201607287XA (da)
WO (1)	WO2015134332A2 (da)
ZA (1)	ZA201606036B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11364292B2 (en)	2015-07-21	2022-06-21	Modernatx, Inc.	CHIKV RNA vaccines
WO2017070624A1 (en)	2015-10-22	2017-04-27	Modernatx, Inc.	Tropical disease vaccines
WO2018232357A1 (en)	2017-06-15	2018-12-20	Modernatx, Inc.	Rna formulations
CA3073211A1 (en)	2017-08-31	2019-03-07	Modernatx, Inc.	Methods of making lipid nanoparticles
US10653767B2 (en)	2017-09-14	2020-05-19	Modernatx, Inc.	Zika virus MRNA vaccines
EP3681523A4 (en) *	2017-09-15	2021-12-29	The Ohio State Innovation Foundation	Vaccines and methods of making and using vaccines for prevention of respiratory syncytial virus (rsv) infections
WO2020018705A1 (en) *	2018-07-17	2020-01-23	Yale University	Methods for treatment of cancer using chikungunya-vsv chimeric virus
EP3852728B1 (en)	2018-09-20	2024-09-18	ModernaTX, Inc.	Preparation of lipid nanoparticles and methods of administration thereof
US12070495B2 (en)	2019-03-15	2024-08-27	Modernatx, Inc.	HIV RNA vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7153510B1 (en) *	1995-05-04	2006-12-26	Yale University	Recombinant vesiculoviruses and their uses
US20070134200A1 (en) *	2003-03-26	2007-06-14	Wyeth	Immunogenic composition and methods
CA2561245C (en) *	2004-04-09	2013-06-18	Wyeth	Synergistic attenuation of vesicular stomatitis virus, vectors thereof and immunogenic compositions thereof
CN101087886B (zh) *	2004-04-09	2013-07-17	惠氏公司	疱疹性口炎病毒、其载体和其免疫原性组合物的协同减毒
US8481023B2 (en) *	2006-09-15	2013-07-09	Ottawa Hospital Research Institute	Oncolytic rhabdovirus
MX342449B (es) *	2007-08-03	2016-09-29	Pasteur Institut	Vectores de transferencia de gen lentiviral y sus aplicaciones medicinales.
CN105039266A (zh) *	2008-03-14	2015-11-11	赛诺菲巴斯德生物制剂有限责任公司	复制缺陷型黄病毒疫苗和疫苗载体
US9707285B2 (en) *	2009-03-16	2017-07-18	Turnstone Limited Partnership	Vaccination methods
AU2010258047B2 (en)	2009-06-08	2016-01-14	The University Of Western Ontario	Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens
WO2011143650A2 (en) *	2010-05-14	2011-11-17	Oregon Health & Science University	Recombinant hcmv and rhcmv vectors and uses thereof
US20130095556A1 (en)	2011-09-21	2013-04-18	International Aids Vaccine Initiative	Novel vesicular stomatitis virus and virus rescue system

2015
- 2015-02-27 US US15/122,695 patent/US9932564B2/en active Active
- 2015-02-27 WO PCT/US2015/018156 patent/WO2015134332A2/en active Application Filing
- 2015-02-27 ES ES15758863T patent/ES2749381T3/es active Active
- 2015-02-27 JP JP2016555578A patent/JP2017508465A/ja active Pending
- 2015-02-27 DK DK15758863.3T patent/DK3113795T3/da active
- 2015-02-27 MX MX2016011300A patent/MX369776B/es active IP Right Grant
- 2015-02-27 AU AU2015225553A patent/AU2015225553B2/en active Active
- 2015-02-27 CN CN201580026511.3A patent/CN106794240A/zh active Pending
- 2015-02-27 SG SG11201607287XA patent/SG11201607287XA/en unknown
- 2015-02-27 CA CA2941261A patent/CA2941261A1/en active Pending
- 2015-02-27 EP EP15758863.3A patent/EP3113795B1/en active Active
- 2015-02-27 KR KR1020167027395A patent/KR102416194B1/ko active IP Right Grant
2016
- 2016-08-30 IL IL247545A patent/IL247545B/en unknown
- 2016-08-31 ZA ZA2016/06036A patent/ZA201606036B/en unknown
2020
- 2020-02-03 JP JP2020015937A patent/JP7454393B2/ja active Active
2022
- 2022-01-31 IL IL290258A patent/IL290258A/en unknown
- 2022-06-14 JP JP2022095401A patent/JP2022126723A/ja active Pending

Also Published As

Publication number	Publication date
EP3113795A2 (en)	2017-01-11
MX369776B (es)	2019-11-21
IL290258A (en)	2022-04-01
JP2022126723A (ja)	2022-08-30
AU2015225553B2 (en)	2020-02-27
US9932564B2 (en)	2018-04-03
KR102416194B1 (ko)	2022-07-04
JP7454393B2 (ja)	2024-03-22
IL247545B (en)	2022-03-01
MX2016011300A (es)	2017-05-08
AU2015225553A1 (en)	2016-09-15
JP2020078318A (ja)	2020-05-28
WO2015134332A3 (en)	2016-01-28
ZA201606036B (en)	2020-02-26
SG11201607287XA (en)	2016-09-29
JP2017508465A (ja)	2017-03-30
US20170067027A1 (en)	2017-03-09
KR20160135740A (ko)	2016-11-28
ES2749381T3 (es)	2020-03-20
WO2015134332A2 (en)	2015-09-11
EP3113795B1 (en)	2019-07-10
EP3113795A4 (en)	2017-07-26
IL247545A0 (en)	2016-11-30
CN106794240A (zh)	2017-05-31
CA2941261A1 (en)	2015-09-11

Publication	Publication Date	Title
DK3393505T3 (da)	2021-05-10	Rekombinante zika-vacciner
DK3108000T3 (da)	2019-10-28	Adeno-associeret virusvektor
DK3393510T3 (da)	2023-03-13	Zikavirusvaccine
DK3145949T3 (da)	2020-06-29	Lentivirale vektorer
GB201401707D0 (en)	2014-03-19	Adeno-associated viral vectors
EP3221456A4 (en)	2018-09-12	Genome-modified recombinant adeno-associated virus vectors
DK3180363T3 (da)	2019-11-04	Sirp-alpha-immunoglobulin fusionsproteiner
DK3207053T3 (da)	2019-11-04	Hidtil ukendte immunogene peptider
IL290258A (en)	2022-04-01	Transgenic Isfahan Viral Vector
DK4089113T3 (da)	2024-02-05	Polypeptider
FR3018972B1 (fr)	2016-04-15	Secure nfc routing
DK3099791T3 (da)	2020-08-24	Protein
DK3164410T3 (da)	2022-03-07	Protein-indvinding
FR3025617B1 (fr)	2016-12-16	Architecture bi-voies
DE112015001058A5 (de)	2016-12-01	Schalter
DK3201222T3 (da)	2019-06-24	Rekombinasemutanter
DK3228706T3 (da)	2021-07-26	Coekspressionsplasmid
DK3184633T3 (da)	2019-10-28	Modificeret beta-galaktosidase
DK3099793T3 (da)	2020-03-16	Protein
DK3129037T3 (da)	2020-02-03	Onkolytiske koppevirusvektorer
DK3183359T3 (da)	2021-02-01	Effektiv valg af rekombinante proteiner
DK3319625T3 (da)	2020-03-30	Immunogene præ-procalcitoninpeptider
DK3302527T3 (da)	2020-03-30	Manipuleret CCL20-låst-dimerpolypeptid
ES2775740T8 (es)	2020-08-06	Péptidos
TH1601000676A (th)	2018-05-24	เพพไทด์